PT Darya-Varia Laboratoria Tbk (DVLA.JK)
IDR 1495.0
(-0.66%)
IDR 1495.0
(-0.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 255.91 Billion IDR | 4.76% |
| 2022 | 262.89 Billion IDR | -5.41% |
| 2021 | 272.74 Billion IDR | -0.01% |
| 2020 | 271.08 Billion IDR | -23.02% |
| 2019 | 352.98 Billion IDR | 7.78% |
| 2018 | 297.07 Billion IDR | 19.22% |
| 2017 | 273.45 Billion IDR | 20.75% |
| 2016 | 255.25 Billion IDR | 69.7% |
| 2015 | 128.22 Billion IDR | 28.72% |
| 2014 | 108.19 Billion IDR | -43.46% |
| 2013 | 159.37 Billion IDR | -14.83% |
| 2012 | 218.32 Billion IDR | 22.47% |
| 2011 | 160.17 Billion IDR | 20.65% |
| 2010 | 150.02 Billion IDR | 9.43% |
| 2009 | 119.32 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 99.44 Billion IDR | 37.52% |
| 2024 Q3 | 49.93 Billion IDR | -32.36% |
| 2024 Q2 | 72.59 Billion IDR | -31.23% |
| 2023 Q4 | 100.07 Billion IDR | 711.79% |
| 2023 FY | - IDR | 4.76% |
| 2023 Q1 | 87.49 Billion IDR | 2548.61% |
| 2023 Q2 | 54.63 Billion IDR | -37.56% |
| 2023 Q3 | 12.32 Billion IDR | -77.44% |
| 2022 Q4 | -3.57 Billion IDR | -1442.72% |
| 2022 Q1 | 186.4 Billion IDR | 248.81% |
| 2022 Q2 | 50.53 Billion IDR | -72.89% |
| 2022 FY | - IDR | -5.41% |
| 2022 Q3 | -231.61 Million IDR | -100.46% |
| 2021 Q4 | -125.26 Billion IDR | -167.7% |
| 2021 FY | - IDR | -0.01% |
| 2021 Q1 | 116.08 Billion IDR | 287.09% |
| 2021 Q2 | 70.61 Billion IDR | -39.17% |
| 2021 Q3 | 185.02 Billion IDR | 162.02% |
| 2020 Q1 | 83.61 Billion IDR | 32.33% |
| 2020 Q4 | 29.99 Billion IDR | 38.99% |
| 2020 Q3 | 21.57 Billion IDR | -80.62% |
| 2020 FY | - IDR | -23.02% |
| 2020 Q2 | 111.31 Billion IDR | 33.13% |
| 2019 Q3 | 89.61 Billion IDR | 90.84% |
| 2019 Q1 | 120.44 Billion IDR | 42.68% |
| 2019 Q2 | 46.95 Billion IDR | -61.01% |
| 2019 FY | - IDR | 7.78% |
| 2019 Q4 | 63.18 Billion IDR | -29.48% |
| 2018 FY | - IDR | 19.22% |
| 2018 Q4 | 84.41 Billion IDR | 16.6% |
| 2018 Q3 | 72.4 Billion IDR | 26.16% |
| 2018 Q2 | 57.38 Billion IDR | -30.75% |
| 2018 Q1 | 82.86 Billion IDR | 1672.39% |
| 2017 Q2 | 48.2 Billion IDR | -55.0% |
| 2017 Q3 | 66.15 Billion IDR | 37.26% |
| 2017 Q1 | 107.11 Billion IDR | 341.25% |
| 2017 FY | - IDR | 20.75% |
| 2017 Q4 | 4.67 Billion IDR | -92.93% |
| 2016 Q2 | 33.52 Billion IDR | -54.16% |
| 2016 Q4 | 24.27 Billion IDR | -67.82% |
| 2016 FY | - IDR | 69.7% |
| 2016 Q1 | 73.14 Billion IDR | 2437.04% |
| 2016 Q3 | 75.43 Billion IDR | 125.0% |
| 2015 Q3 | 22.44 Billion IDR | 1.84% |
| 2015 FY | - IDR | 28.72% |
| 2015 Q1 | 74.45 Billion IDR | 986.22% |
| 2015 Q2 | 22.03 Billion IDR | -70.4% |
| 2015 Q4 | 2.88 Billion IDR | -87.15% |
| 2014 Q1 | -20.64 Billion IDR | -149.34% |
| 2014 FY | - IDR | -43.46% |
| 2014 Q4 | 6.85 Billion IDR | -78.26% |
| 2014 Q3 | 31.53 Billion IDR | -58.9% |
| 2014 Q2 | 76.72 Billion IDR | 471.68% |
| 2013 Q3 | 19.1 Billion IDR | -64.42% |
| 2013 Q1 | 65.6 Billion IDR | 10.8% |
| 2013 FY | - IDR | -14.83% |
| 2013 Q4 | 41.83 Billion IDR | 118.99% |
| 2013 Q2 | 53.69 Billion IDR | -18.16% |
| 2012 Q3 | 36.99 Billion IDR | 0.0% |
| 2012 FY | - IDR | 22.47% |
| 2012 Q4 | 59.21 Billion IDR | 60.06% |
| 2011 FY | - IDR | 20.65% |
| 2010 FY | - IDR | 9.43% |
| 2009 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Merck Tbk | 239.49 Billion IDR | -6.857% |
| PT Phapros, Tbk | 120.77 Billion IDR | -111.895% |
| PT Pyridam Farma Tbk | 60.69 Billion IDR | -321.625% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | 1323.93 Billion IDR | 80.67% |
| PT Tempo Scan Pacific Tbk | 1997.6 Billion IDR | 87.189% |